First Opinion on STAT is a platform for insightful articles on life sciences, written by experts in the field. Readers can engage in discussions by submitting Letters to the Editor in response to the articles. Recent topics include the importance of institutional neutrality in universities, critique of Trump’s handling of Covid-19, and challenges in conducting trials for ultra-rare diseases like Barth syndrome. Experts emphasize the need for rare disease patients to not be overlooked in the current therapeutic revolution. They also commend the FDA’s efforts to establish a Rare Disease Innovation Hub to provide guidance and streamline the drug development process for these patients.
Source link
STAT readers on the Rare Disease Innovation Hub and more
